Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.

Zhao F, Afonso S, Lindner S, Hartmann A, Löschmann I, Nilsson B, Ekdahl KN, Weber LT, Habbig S, Schalk G, Kirschfink M, Zipfel PF, Skerka C.

Front Immunol. 2019 May 31;10:1030. doi: 10.3389/fimmu.2019.01030. eCollection 2019.

2.

Effects of Hemodiafiltration versus Conventional Hemodialysis in Children with ESKD: The HDF, Heart and Height Study.

Shroff R, Smith C, Ranchin B, Bayazit AK, Stefanidis CJ, Askiti V, Azukaitis K, Canpolat N, Ağbaş A, Aitkenhead H, Anarat A, Aoun B, Aofolaju D, Bakkaloglu SA, Bhowruth D, Borzych-Dużałka D, Bulut IK, Büscher R, Deanfield J, Dempster C, Duzova A, Habbig S, Hayes W, Hegde S, Krid S, Licht C, Litwin M, Mayes M, Mir S, Nemec R, Obrycki L, Paglialonga F, Picca S, Samaille C, Shenoy M, Sinha MD, Spasojevic B, Stronach L, Vidal E, Vondrák K, Yilmaz A, Zaloszyc A, Fischbach M, Schmitt CP, Schaefer F.

J Am Soc Nephrol. 2019 Apr;30(4):678-691. doi: 10.1681/ASN.2018100990. Epub 2019 Mar 7.

PMID:
30846560
3.

Inactivation of Apoptosis Antagonizing Transcription Factor in tubular epithelial cells induces accumulation of DNA damage and nephronophthisis.

Jain M, Kaiser RWJ, Bohl K, Hoehne M, Göbel H, Bartram MP, Habbig S, Müller RU, Fogo AB, Benzing T, Schermer B, Höpker K, Slaats GG.

Kidney Int. 2019 Apr;95(4):846-858. doi: 10.1016/j.kint.2018.10.034. Epub 2019 Feb 13.

PMID:
30770218
4.

HNF1B nephropathy has a slow-progressive phenotype in childhood-with the exception of very early onset cases: results of the German Multicenter HNF1B Childhood Registry.

Okorn C, Goertz A, Vester U, Beck BB, Bergmann C, Habbig S, König J, Konrad M, Müller D, Oh J, Ortiz-Brüchle N, Patzer L, Schild R, Seeman T, Staude H, Thumfart J, Tönshoff B, Walden U, Weber L, Zaniew M, Zappel H, Hoyer PF, Weber S.

Pediatr Nephrol. 2019 Jun;34(6):1065-1075. doi: 10.1007/s00467-018-4188-8. Epub 2019 Jan 21.

PMID:
30666461
5.

Discontinuation of maintenance therapy in frequently relapsing nephrotic syndrome
.

Vogd J, Hackl A, Habbig S, Lechner F, Akarkach A, Weber LT, Ehren R.

Clin Nephrol. 2019 Jan;91(1):25-31. doi: 10.5414/CN109532.

PMID:
30369402
6.

Effect of haemodiafiltration vs conventional haemodialysis on growth and cardiovascular outcomes in children - the HDF, heart and height (3H) study.

Shroff R, Bayazit A, Stefanidis CJ, Askiti V, Azukaitis K, Canpolat N, Agbas A, Anarat A, Aoun B, Bakkaloglu S, Bhowruth D, Borzych-Dużałka D, Bulut IK, Büscher R, Dempster C, Duzova A, Habbig S, Hayes W, Hegde S, Krid S, Licht C, Litwin M, Mayes M, Mir S, Nemec R, Obrycki L, Paglialonga F, Picca S, Ranchin B, Samaille C, Shenoy M, Sinha M, Smith C, Spasojevic B, Vidal E, Vondrák K, Yilmaz A, Zaloszyc A, Fischbach M, Schaefer F, Schmitt CP.

BMC Nephrol. 2018 Aug 10;19(1):199. doi: 10.1186/s12882-018-0998-y.

7.

Targeted deletion of the AAA-ATPase Ruvbl1 in mice disrupts ciliary integrity and causes renal disease and hydrocephalus.

Dafinger C, Rinschen MM, Borgal L, Ehrenberg C, Basten SG, Franke M, Höhne M, Rauh M, Göbel H, Bloch W, Wunderlich FT, Peters DJM, Tasche D, Mishra T, Habbig S, Dötsch J, Müller RU, Brüning JC, Persigehl T, Giles RH, Benzing T, Schermer B, Liebau MC.

Exp Mol Med. 2018 Jun 28;50(6):75. doi: 10.1038/s12276-018-0108-z.

8.

Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease.

Lerch C, Shroff R, Wan M, Rees L, Aitkenhead H, Kaplan Bulut I, Thurn D, Karabay Bayazit A, Niemirska A, Canpolat N, Duzova A, Azukaitis K, Yilmaz E, Yalcinkaya F, Harambat J, Kiyak A, Alpay H, Habbig S, Zaloszyc A, Soylemezoglu O, Candan C, Rosales A, Melk A, Querfeld U, Leifheit-Nestler M, Sander A, Schaefer F, Haffner D; 4C study consortium ; ESPN CKD-MBD working group .

Nephrol Dial Transplant. 2018 Dec 1;33(12):2208-2217. doi: 10.1093/ndt/gfy012.

PMID:
29481636
9.

Perinatal Diagnosis, Management, and Follow-up of Cystic Renal Diseases: A Clinical Practice Recommendation With Systematic Literature Reviews.

Gimpel C, Avni FE, Bergmann C, Cetiner M, Habbig S, Haffner D, König J, Konrad M, Liebau MC, Pape L, Rellensmann G, Titieni A, von Kaisenberg C, Weber S, Winyard PJD, Schaefer F.

JAMA Pediatr. 2018 Jan 1;172(1):74-86. doi: 10.1001/jamapediatrics.2017.3938.

PMID:
29181500
10.

Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring.

Hackl A, Becker JU, Körner LM, Ehren R, Habbig S, Nüsken E, Nüsken KD, Ebner K, Liebau MC, Müller C, Pohl M, Weber LT.

Pediatr Nephrol. 2018 Apr;33(4):619-629. doi: 10.1007/s00467-017-3846-6. Epub 2017 Nov 25.

PMID:
29177628
11.

Phenotypic Spectrum of Children with Nephronophthisis and Related Ciliopathies.

König J, Kranz B, König S, Schlingmann KP, Titieni A, Tönshoff B, Habbig S, Pape L, Häffner K, Hansen M, Büscher A, Bald M, Billing H, Schild R, Walden U, Hampel T, Staude H, Riedl M, Gretz N, Lablans M, Bergmann C, Hildebrandt F, Omran H, Konrad M; Gesellschaft für Pädiatrische Nephrologie (GPN).

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1974-1983. doi: 10.2215/CJN.01280217. Epub 2017 Nov 16.

12.

Prenatal parental decision-making and postnatal outcome in renal oligohydramnios.

Mehler K, Gottschalk I, Burgmaier K, Volland R, Büscher AK, Feldkötter M, Keller T, Weber LT, Kribs A, Habbig S.

Pediatr Nephrol. 2018 Apr;33(4):651-659. doi: 10.1007/s00467-017-3812-3. Epub 2017 Oct 27.

PMID:
29075889
13.

Early Effects of Renal Replacement Therapy on Cardiovascular Comorbidity in Children With End-Stage Kidney Disease: Findings From the 4C-T Study.

Schmidt BMW, Sugianto RI, Thurn D, Azukaitis K, Bayazit AK, Canpolat N, Eroglu AG, Caliskan S, Doyon A, Duzova A, Karagoz T, Anarat A, Deveci M, Mir S, Ranchin B, Shroff R, Baskin E, Litwin M, Özcakar ZB, Büscher R, Soylemezoglu O, Dusek J, Kemper MJ, Matteucci MC, Habbig S, Laube G, Wühl E, Querfeld U, Sander A, Schaefer F, Melk A; 4C Study Consortium.

Transplantation. 2018 Mar;102(3):484-492. doi: 10.1097/TP.0000000000001948.

PMID:
28926375
14.

Low renal but high extrarenal phenotype variability in Schimke immuno-osseous dysplasia.

Lipska-Ziętkiewicz BS, Gellermann J, Boyer O, Gribouval O, Ziętkiewicz S, Kari JA, Shalaby MA, Ozaltin F, Dusek J, Melk A, Bayazit AK, Massella L, Hyla-Klekot L, Habbig S, Godron A, Szczepańska M, Bieniaś B, Drożdż D, Odeh R, Jarmużek W, Zachwieja K, Trautmann A, Antignac C, Schaefer F; PodoNet Consortium.

PLoS One. 2017 Aug 10;12(8):e0180926. doi: 10.1371/journal.pone.0180926. eCollection 2017.

15.

Dyslipidemia after pediatric renal transplantation-The impact of immunosuppressive regimens.

Habbig S, Volland R, Krupka K, Querfeld U, Dello Strologo L, Noyan A, Yalcinkaya F, Topaloglu R, Webb NJ, Kemper MJ, Pape L, Bald M, Kranz B, Taylan C, Höcker B, Tönshoff B, Weber LT.

Pediatr Transplant. 2017 May;21(3). doi: 10.1111/petr.12914. Epub 2017 Mar 28.

PMID:
28370750
16.

Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.

Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB, Weber LT, Habbig S.

Pediatr Nephrol. 2017 Jun;32(6):1081-1087. doi: 10.1007/s00467-017-3612-9. Epub 2017 Feb 20. Review.

PMID:
28220235
17.

Disorders of fatty acid oxidation and autosomal recessive polycystic kidney disease-different clinical entities and comparable perinatal renal abnormalities.

Hackl A, Mehler K, Gottschalk I, Vierzig A, Eydam M, Hauke J, Beck BB, Liebau MC, Ensenauer R, Weber LT, Habbig S.

Pediatr Nephrol. 2017 May;32(5):791-800. doi: 10.1007/s00467-016-3556-5. Epub 2017 Jan 12.

PMID:
28083701
18.

Extrarenal Manifestations in Shigatoxin-associated Haemolytic Uremic Syndrome.

Matthies J, Hünseler C, Ehren R, Volland R, Körber F, Hoppe B, Weber LT, Habbig S.

Klin Padiatr. 2016 Jul;228(4):181-8. doi: 10.1055/s-0042-108444. Epub 2016 Jun 13.

PMID:
27294341
19.

Three-layered proteomic characterization of a novel ACTN4 mutation unravels its pathogenic potential in FSGS.

Bartram MP, Habbig S, Pahmeyer C, Höhne M, Weber LT, Thiele H, Altmüller J, Kottoor N, Wenzel A, Krueger M, Schermer B, Benzing T, Rinschen MM, Beck BB.

Hum Mol Genet. 2016 Mar 15;25(6):1152-64. doi: 10.1093/hmg/ddv638. Epub 2016 Jan 5.

PMID:
26740551
20.

Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH.

Habbig S, Bergmann C, Weber LT.

Am J Kidney Dis. 2016 Mar;67(3):532-3. doi: 10.1053/j.ajkd.2015.11.009. Epub 2015 Dec 23. No abstract available.

PMID:
26724167
21.

Ciliopathies - from rare inherited cystic kidney diseases to basic cellular function.

Habbig S, Liebau MC.

Mol Cell Pediatr. 2015 Dec;2(1):8. doi: 10.1186/s40348-015-0019-1. Epub 2015 May 19.

22.

Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome: Does Therapeutic Drug Monitoring Make a Difference?

Hackl Á, Cseprekál O, Gessner M, Liebau MC, Habbig S, Ehren R, Müller C, Taylan C, Dötsch J, Weber LT.

Ther Drug Monit. 2016 Apr;38(2):274-9. doi: 10.1097/FTD.0000000000000258.

PMID:
26488204
23.

Loss of Dgcr8-mediated microRNA expression in the kidney results in hydronephrosis and renal malformation.

Bartram MP, Dafinger C, Habbig S, Benzing T, Schermer B, Müller RU.

BMC Nephrol. 2015 Apr 14;16:55. doi: 10.1186/s12882-015-0053-1.

24.

Label-free quantitative proteomic analysis of the YAP/TAZ interactome.

Kohli P, Bartram MP, Habbig S, Pahmeyer C, Lamkemeyer T, Benzing T, Schermer B, Rinschen MM.

Am J Physiol Cell Physiol. 2014 May 1;306(9):C805-18. doi: 10.1152/ajpcell.00339.2013. Epub 2014 Feb 26.

25.

Diagnosis of Alport syndrome--search for proteomic biomarkers in body fluids.

Pohl M, Danz K, Gross O, John U, Urban J, Patzer L, Habbig S, Feldkötter M, Witzke O, Walther M, Rhode H.

Pediatr Nephrol. 2013 Nov;28(11):2117-23. doi: 10.1007/s00467-013-2533-5. Epub 2013 Jun 23.

PMID:
23793922
26.

Mutations in NEK8 link multiple organ dysplasia with altered Hippo signalling and increased c-MYC expression.

Frank V, Habbig S, Bartram MP, Eisenberger T, Veenstra-Knol HE, Decker C, Boorsma RA, Göbel H, Nürnberg G, Griessmann A, Franke M, Borgal L, Kohli P, Völker LA, Dötsch J, Nürnberg P, Benzing T, Bolz HJ, Johnson C, Gerkes EH, Schermer B, Bergmann C.

Hum Mol Genet. 2013 Jun 1;22(11):2177-85. doi: 10.1093/hmg/ddt070. Epub 2013 Feb 14.

PMID:
23418306
27.

Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions.

Beck BB, Hoyer-Kuhn H, Göbel H, Habbig S, Hoppe B.

Expert Opin Investig Drugs. 2013 Jan;22(1):117-29. doi: 10.1517/13543784.2013.741587. Epub 2012 Nov 21. Review.

PMID:
23167815
28.

The ciliopathy disease protein NPHP9 promotes nuclear delivery and activation of the oncogenic transcriptional regulator TAZ.

Habbig S, Bartram MP, Sägmüller JG, Griessmann A, Franke M, Müller RU, Schwarz R, Hoehne M, Bergmann C, Tessmer C, Reinhardt HC, Burst V, Benzing T, Schermer B.

Hum Mol Genet. 2012 Dec 15;21(26):5528-38. doi: 10.1093/hmg/dds408. Epub 2012 Oct 1.

PMID:
23026745
29.

Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies.

Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido EC, Hoppe B.

Eur J Hum Genet. 2013 Feb;21(2):162-72. doi: 10.1038/ejhg.2012.139. Epub 2012 Jul 11.

30.

The ciliary protein nephrocystin-4 translocates the canonical Wnt regulator Jade-1 to the nucleus to negatively regulate β-catenin signaling.

Borgal L, Habbig S, Hatzold J, Liebau MC, Dafinger C, Sacarea I, Hammerschmidt M, Benzing T, Schermer B.

J Biol Chem. 2012 Jul 20;287(30):25370-80. doi: 10.1074/jbc.M112.385658. Epub 2012 May 31.

31.

Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease.

Hueppelshaeuser R, von Unruh GE, Habbig S, Beck BB, Buderus S, Hesse A, Hoppe B.

Pediatr Nephrol. 2012 Jul;27(7):1103-9. doi: 10.1007/s00467-012-2126-8. Epub 2012 Feb 25.

PMID:
22366809
32.

Liver cell transplantation in severe infantile oxalosis--a potential bridging procedure to orthotopic liver transplantation?

Beck BB, Habbig S, Dittrich K, Stippel D, Kaul I, Koerber F, Goebel H, Salido EC, Kemper M, Meyburg J, Hoppe B.

Nephrol Dial Transplant. 2012 Jul;27(7):2984-9. doi: 10.1093/ndt/gfr776. Epub 2012 Jan 28.

PMID:
22287658
33.

Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.

Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J.

Nephrol Dial Transplant. 2012 May;27(5):1910-5. doi: 10.1093/ndt/gfr548. Epub 2011 Nov 9.

PMID:
22076431
34.

Nephrocalcinosis and urolithiasis in children.

Habbig S, Beck BB, Hoppe B.

Kidney Int. 2011 Dec;80(12):1278-91. doi: 10.1038/ki.2011.336. Epub 2011 Sep 28. Erratum in: Kidney Int. 2012 Aug;82(4):493-7.

35.

NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway.

Habbig S, Bartram MP, Müller RU, Schwarz R, Andriopoulos N, Chen S, Sägmüller JG, Hoehne M, Burst V, Liebau MC, Reinhardt HC, Benzing T, Schermer B.

J Cell Biol. 2011 May 16;193(4):633-42. doi: 10.1083/jcb.201009069. Epub 2011 May 9.

36.

Nephrocystin-4 regulates Pyk2-induced tyrosine phosphorylation of nephrocystin-1 to control targeting to monocilia.

Liebau MC, Höpker K, Müller RU, Schmedding I, Zank S, Schairer B, Fabretti F, Höhne M, Bartram MP, Dafinger C, Hackl M, Burst V, Habbig S, Zentgraf H, Blaukat A, Walz G, Benzing T, Schermer B.

J Biol Chem. 2011 Apr 22;286(16):14237-45. doi: 10.1074/jbc.M110.165464. Epub 2011 Feb 28.

37.

Liver fibrosis in recessive multicystic kidney diseases: transient elastography for early detection.

Kummer S, Sagir A, Pandey S, Feldkötter M, Habbig S, Körber F, Ney D, Hoppe B, Häussinger D, Mayatepek E, Oh J.

Pediatr Nephrol. 2011 May;26(5):725-31. doi: 10.1007/s00467-011-1771-7. Epub 2011 Feb 1.

PMID:
21279811
38.

Platelet-associated complement factor H in healthy persons and patients with atypical HUS.

Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH.

Blood. 2009 Nov 12;114(20):4538-45. doi: 10.1182/blood-2009-03-205096. Epub 2009 Aug 24.

39.

Renal allograft calcification -- prevalence and etiology in pediatric patients.

Habbig S, Beck BB, Feldkötter M, Körber F, Laffeber C, Verkoelen C, Mihatsch MJ, Hoppe B.

Am J Nephrol. 2009;30(3):194-200. doi: 10.1159/000217585. Epub 2009 Apr 30.

PMID:
19407442
40.

Evolution of PTLD following renal transplantation in a child.

Markert E, Siebolts U, Habbig S, Odenthal M, Dienes HP, Stippel DL, Hoppe B, Wickenhauser C.

Pediatr Transplant. 2009 May;13(3):379-83. doi: 10.1111/j.1399-3046.2008.00988.x. Epub 2008 Oct 7.

PMID:
19017284
41.

C3 deposition glomerulopathy due to a functional factor H defect.

Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, Kirschfink M, Hoppe B, Zipfel PF, Licht C.

Kidney Int. 2009 Jun;75(11):1230-1234. doi: 10.1038/ki.2008.354. Epub 2008 Jul 16. No abstract available.

42.

The case: A boy with recurrent stones.

Beck BB, Laube N, Habbig S, Feldkötter M, Fries JW, Hoppe B.

Kidney Int. 2008 Jul;74(1):133-4. doi: 10.1038/ki.2008.165. No abstract available.

43.

Post-appendectomy intra-abdominal abscesses--can they successfully be managed with the sole use of antibiotic therapy?

Forgues D, Habbig S, Diallo AF, Kalfa N, Lopez M, Allal H, Guibal MP, Sabatier-Laval E, Galifer RB.

Eur J Pediatr Surg. 2007 Apr;17(2):104-9.

PMID:
17503303
44.

[Quality of guidelines for the treatment of alcohol related disorders -- a systematic review and content analysis].

Berner MM, Habbig S, Härter M.

Fortschr Neurol Psychiatr. 2004 Dec;72(12):696-704. German.

PMID:
15580534

Supplemental Content

Loading ...
Support Center